Japanese Knotweed for Health & Longevity - Quick Reference Sheet

Japanese Knotweed for Health & Longevity

Created on 07/29/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Japanese knotweed is the cheapest practical source of resveratrol. Its most credible benefits are modest and centered on the heart and metabolism: better blood-vessel flexibility, lower blood pressure at higher doses, and improved blood sugar in people with diabetes. Bone and brain effects are preliminary, and longevity claims rest on animal studies. Risks are mostly mild digestive upset. (Full Review)

Protocol

Standard Dose
150–500 mg/day
Trans-resveratrol from standardized knotweed extract; some longevity users to ~1,000 mg/day
Timing
Morning, with food
With a fat-containing meal to improve absorption
Frequency
Once or twice daily
Up to ~250 mg once daily; 500–1,000 mg split morning and evening
Time to effect
Blood Pressure
Weeks to months
With consistent daily use
Blood Sugar
Weeks to months
In people with type 2 diabetes
Bone Density
~12 months
In postmenopausal women

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Hormone-sensitive cancers (breast, uterine, ovarian)
  • Active bleeding, bleeding disorder, or surgery within 1–2 weeks
  • Severe liver impairment (Child-Pugh Class C)
Key Interactions
  • Anticoagulants and antiplatelet drugs (warfarin, clopidogrel, apixaban, rivaroxaban)
  • CYP3A4-metabolized drugs (statins, calcium-channel blockers, immunosuppressants)
  • CYP2C9 substrates (warfarin, NSAIDs, phenytoin)
  • Antihypertensive drugs (ACE inhibitors, ARBs, calcium-channel blockers)
  • Antidiabetic drugs (metformin, sulfonylureas, insulin)
  • Aspirin and other NSAIDs (ibuprofen, naproxen)
  • Stimulant-laxative products
  • Bleeding-risk supplements (fish oil, ginkgo, garlic, vitamin E, curcumin)
  • Quercetin and piperine

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal disturbance
  • Low: Increased bleeding tendency; estrogenic activity in hormone-sensitive conditions; emodin-related liver and cellular toxicity
  • Speculative: Nephrotoxicity at very high doses; genotoxicity of chronic anthraquinone exposure

Monitoring

Marker Target Why
Systolic/Diastolic Blood Pressure ~110–120 / 70–78 mmHg Primary cardiovascular response marker
Fasting Glucose 75–86 mg/dL Tracks glycemic effect, esp. in diabetics
HbA1c <5.4% Average blood sugar over ~3 months
hs-CRP <1.0 mg/L Systemic inflammation response
ALT / AST <25 U/L (ALT), <25 U/L (AST) Screens for rare emodin-related liver stress
Lipid Panel (LDL, HDL, triglycerides) LDL <100, HDL >55, TG <90 mg/dL Secondary cardiometabolic effect
eGFR / Creatinine eGFR >90 mL/min/1.73m² Safety at higher doses
Estradiol Age/sex-appropriate Context for phytoestrogen exposure

Cadence: Recheck at 4–12 weeks after starting, then every 3–6 months on higher doses (or every 6–12 months for low-dose maintenance)

Qualitative Assessment

  • Energy levels and daytime alertness
  • Cognitive clarity and memory
  • Exercise capacity and recovery
  • Bowel regularity (watch for loose stools signaling excess emodin)
  • Blood-pressure-related symptoms such as lightheadedness